Pulmonary Hypertension: High Blood Pressure in the Lungs

Pulmonary hypertension (PH) is a condition defined by abnormally elevated pressure within the pulmonary arteries — the vessels that carry blood from the right side of the heart into the lungs. It is classified into five distinct groups by the World Health Organization based on underlying cause, and it affects an estimated 1% of the global population, with prevalence rising to as high as 10% among adults over age 65 (World Health Organization, Global Report on Hypertension 2023). Left unaddressed, pulmonary hypertension progressively damages the right ventricle and carries significant morbidity. This page covers the definition, physiological mechanism, clinical scenarios where PH appears, and the diagnostic boundaries used to distinguish its subtypes.

Definition and Scope

Pulmonary hypertension is formally defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, measured by right heart catheterization. This threshold was updated in the 2022 ESC/ERS Guidelines for Pulmonary Hypertension, lowering the prior cutoff of 25 mmHg to improve early detection (European Society of Cardiology / European Respiratory Society, 2022 ESC/ERS PH Guidelines).

The condition sits at the intersection of pulmonary medicine and cardiology. Pulmonologists, cardiologists, and specialized PH centers jointly manage moderate-to-severe cases. The regulatory and clinical oversight landscape governing pulmonary conditions — including FDA-approved therapies and national coverage determinations from the Centers for Medicare & Medicaid Services (CMS) — applies directly to how PH is diagnosed and treated in the United States.

The WHO classification system, adopted by the 6th World Symposium on Pulmonary Hypertension (2018), organizes PH into five groups:

  1. Group 1 — Pulmonary Arterial Hypertension (PAH): Idiopathic, heritable, drug-induced, or associated with connective tissue disease, HIV, or congenital heart disease. This is the subtype most studied in targeted therapy trials.
  2. Group 2 — PH Due to Left Heart Disease: The most common form overall, caused by heart failure with reduced or preserved ejection fraction, or valvular disease.
  3. Group 3 — PH Due to Lung Disease or Hypoxia: Associated with COPD, pulmonary fibrosis, obstructive sleep apnea, or high-altitude exposure.
  4. Group 4 — Chronic Thromboembolic PH (CTEPH): Results from unresolved clot obstruction following pulmonary embolism.
  5. Group 5 — PH with Unclear or Multifactorial Mechanisms: Includes hematologic disorders, sarcoidosis, and metabolic diseases.

How It Works

Under normal physiology, the pulmonary circulation is a low-resistance, high-flow system. Resting mPAP in healthy adults typically ranges from 12 to 16 mmHg (ESC/ERS 2022 Guidelines).

In pulmonary hypertension, three interrelated pathological processes drive pressure elevation:

In Group 1 PAH, disrupted signaling in three established molecular pathways — the prostacyclin pathway, the endothelin pathway, and the nitric oxide/cGMP pathway — drives much of the vasoconstriction and remodeling. All three pathways are the targets of FDA-approved therapies for PAH.

The right ventricle (RV) compensates initially by hypertrophying — thickening its walls to generate higher pressure output. Over time, this compensatory response fails, leading to RV dilation, tricuspid regurgitation, reduced cardiac output, and ultimately right heart failure. The trajectory from compensated to decompensated RV function is a primary predictor of survival in PAH, as documented in the REVEAL Registry, a North American multicenter observational cohort (CHEST Journal, McLaughlin et al., 2012).

Understanding how the lungs contribute to — and are damaged by — elevated vascular pressure is inseparable from understanding how the lungs work as gas-exchange organs.

Common Scenarios

Pulmonary hypertension presents across a wide range of clinical contexts. The five scenarios below represent the settings in which it is most frequently encountered:

  1. Unexplained exertional dyspnea in a middle-aged woman — Idiopathic PAH has a female-to-male ratio of approximately 2.3:1 (REVEAL Registry data), and exertional breathlessness is the most common presenting symptom, often preceding diagnosis by 2 years.
  2. Heart failure with preserved ejection fraction (HFpEF) — Group 2 PH is the most prevalent subtype in hospital cardiology settings; any patient with HFpEF and worsening symptoms warrants right heart catheterization assessment.
  3. Advanced COPD or pulmonary fibrosis — Group 3 PH complicates a significant proportion of cases with COPD or fibrotic lung disease, and it worsens prognosis independently of underlying lung function.
  4. Post-pulmonary embolism follow-up — Approximately 0.5% to 3.8% of survivors of acute pulmonary embolism develop CTEPH (2022 ESC/ERS Guidelines), making systematic echocardiographic follow-up standard in symptomatic patients.
  5. Connective tissue disease screening — Systemic sclerosis (scleroderma) carries the highest PAH risk among autoimmune conditions; annual echocardiographic screening is recommended by EULAR guidelines.

Decision Boundaries

Accurate classification of PH subtype determines treatment, because therapies effective for Group 1 PAH are not indicated — and may be harmful — in Group 2 PH. The following boundaries define the diagnostic decision tree:

Echocardiography vs. Right Heart Catheterization
Echocardiography is the standard screening tool, using estimated right ventricular systolic pressure (RVSP) and tricuspid regurgitation velocity as surrogates. However, right heart catheterization (RHC) is the definitive confirmatory test. The 2022 ESC/ERS Guidelines assign RHC a Class I, Level C recommendation for confirming PH before initiating therapy.

Pre-capillary vs. Post-capillary PH
RHC distinguishes pre-capillary from post-capillary disease using pulmonary arterial wedge pressure (PAWP):
- PAWP ≤ 15 mmHg = pre-capillary PH (Groups 1, 3, 4, 5)
- PAWP > 15 mmHg = post-capillary PH (Group 2, left heart disease)

This single hemodynamic boundary separates patients who may benefit from PAH-targeted therapies from those for whom such therapies are contraindicated.

Vasoreactivity Testing
Within Group 1 PAH, a vasoreactivity challenge during RHC — using inhaled nitric oxide, intravenous epoprostenol, or adenosine — identifies the approximately 10% of idiopathic PAH patients who respond to high-dose calcium channel blockers, a substantially different and less intensive treatment path.

Risk Stratification
The ESC/ERS 2022 Guidelines formalize a four-tier risk stratification system (low, intermediate-low, intermediate-high, high) based on WHO functional class, 6-minute walk distance, BNP/NT-proBNP levels, and RV imaging. Risk tier at first assessment and change in risk tier at follow-up are the primary benchmarks guiding escalation of therapy.

The broader resource index for pulmonary medicine topics provides structured access to related conditions within this diagnostic space, including pulmonary embolism and pulmonary fibrosis, both of which intersect with PH pathophysiology.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)